Table 5.
Chronic GVHD
| n | Any chronic GVHD | Extensive chronic GVHD | |||||
|---|---|---|---|---|---|---|---|
| 3-y (95% CI) | HR (95% CI)* | P * | 3-y (95% CI) | HR (95% CI)* | P * | ||
| Donor type | |||||||
| MUD | 974 | 0.30 (0.27, 0.34) | Reference | .50 | 0.13 (0.10, 0.15) | Reference | 1.00 |
| Haplo | 487 | 0.28 (0.24, 0.32) | 1.09 (0.85, 1.39) | 0.09 (0.07, 0.12) | 1.00 (0.69, 1.45) | ||
| Recipient age, y | |||||||
| <30 | 579 | 0.31 (0.27, 0.35) | Reference | .76 | 0.11 (0.08, 0.14) | Reference | .57 |
| 30-39 | 281 | 0.28 (0.23, 0.34) | 0.87 (0.67, 1.14) | 0.13 (0.09, 0.17) | 1.24 (0.81, 1.89) | ||
| 40-54 | 350 | 0.30 (0.25, 0.36) | 0.94 (0.73, 1.21) | 0.12 (0.09, 0.16) | 1.02 (0.69, 1.52) | ||
| ≥55 | 251 | 0.28 (0.22, 0.34) | 0.89 (0.65, 1.22) | 0.11 (0.07, 0.15) | 0.86 (0.53, 1.41) | ||
| KPS † | |||||||
| 90-100 | 978 | 0.31 (0.28, 0.34) | Reference | .033 | 0.11 (0.09, 0.14) | Reference | .48 |
| ≤80 | 388 | 0.24 (0.20, 0.29) | 0.75 (0.58, 0.98) | 0.11 (0.08, 0.14) | 0.87 (0.59, 1.28) | ||
| ALL subtype | |||||||
| B-ALL | 1044 | 0.31 (0.28, 0.34) | Reference | .72 | 0.12 (0.10, 0.14) | Reference | .66 |
| T-ALL | 322 | 0.28 (0.23, 0.33) | 0.97 (0.76, 1.24) | 0.10 (0.07, 0.14) | 0.91 (0.60, 1.40) | ||
| Other | 95 | 0.25 (0.15, 0.36) | 0.83 (0.52, 1.31) | 0.09 (0.04, 0.17) | 0.71 (0.32, 1.57) | ||
| Months from diagnosis to HCT | |||||||
| ≤6 | 398 | 0.34 (0.29, 0.39) | Reference | .45 | 0.13 (0.10, 0.17) | Reference | .098 |
| >6-12 | 510 | 0.30 (0.25, 0.34) | 0.89 (0.69, 1.14) | 0.10 (0.07, 0.13) | 0.80 (0.52, 1.23) | ||
| >12 | 553 | 0.26 (0.22, 0.30) | 1.04 (0.75, 1.44) | 0.12 (0.09, 0.15) | 1.35 (0.80, 2.26) | ||
| HCT Comorbidity Index † | |||||||
| 0 | 147 | 0.27 (0.19, 0.36) | Reference | .81 | 0.09 (0.05, 0.14) | Reference | .39 |
| 1-2 | 92 | 0.27 (0.18, 0.37) | 1.20 (0.68,2.10) | 0.14 (0.07, 0.22) | 1.72 (0.74, 4.00) | ||
| >2 | 94 | 0.25 (0.16, 0.36) | 1.13 (0.60, 2.13) | 0.13 (0.06, 0.22) | 1.60 (0.65, 3.97) | ||
| Donor age, y † | |||||||
| <30 | 342 | 0.30 (0.25, 0.36) | Reference | .49 | 0.12 (0.09, 0.16) | Reference | .65 |
| 30-49 | 443 | 0.33 (0.29, 0.38) | 1.06 (0.81, 1.40) | 0.12 (0.09, 0.16) | 0.94 (0.60, 1.46) | ||
| ≥50 | 127 | 0.25 (0.18, 0.34) | 0.84 (0.57, 1.24) | 0.08 (0.04, 0.14) | 0.72 (0.35, 1.45) | ||
| Female-to-male HCT † | |||||||
| No | 1172 | 0.30 (0.27, 0.33) | Reference | .95 | 0.12 (0.10, 0.14) | Reference | .83 |
| Yes | 262 | 0.29 (0.23, 0.35) | 1.01 (0.76, 1.34) | 0.10 (0.07, 0.14) | 1.06 (0.65, 1.71) | ||
| CMV serostatus † | |||||||
| D+/R+ | 581 | 0.29 (0.25, 0.33) | Reference | .94 | 0.11 (0.08, 0.14) | Reference | .88 |
| D+/R− | 130 | 0.30 (0.22, 0.38) | 0.96 (0.66, 1.39) | 0.13 (0.08, 0.20) | 1.07 (0.62, 1.84) | ||
| D−/R+ | 366 | 0.28 (0.23, 0.33) | 0.98 (0.75, 1.27) | 0.11 (0.08, 0.15) | 1.00 (0.65, 1.53) | ||
| D−/R− | 318 | 0.33 (0.28, 0.39) | 1.06 (0.80, 1.40) | 0.11 (0.08, 0.15) | 0.86 (0.55, 1.34) | ||
| Stem cell source | |||||||
| PB | 1056 | 0.30 (0.27, 0.33) | Reference | .72 | 0.12 (0.10, 0.14) | Reference | .25 |
| BM | 405 | 0.28 (0.24, 0.33) | 0.96 (0.76, 1.20) | 0.10 (0.07, 0.13) | 0.80 (0.55, 1.17) | ||
| Transplant period | |||||||
| 2005-2012 | 695 | 0.32 (0.28, 0.36) | Reference | .009 | 0.14 (0.12, 0.17) | Reference | <.001 |
| 2013-2018 | 766 | 0.27 (0.24, 0.31) | 0.77 (0.63, 0.94) | 0.09 (0.07, 0.11) | 0.55 (0.40, 0.77) | ||
*
Based on the multivariable proportional subdistribution hazards model for competing risks adjusted for KPS, months from diagnosis to HCT, and transplant period, and stratified by matching variables: sex, cytogenetic risk, Ph status, disease stage, and conditioning intensity. The robust sandwich covariance matrix estimate was used to adjust for within-center correlation.
†
Patients who had missing values were included in the model when the variable was covariates, but were excluded when the variable was predictor of interest.